Nearly two years after the first U.S. approval of Eli Lilly's breast cancer drug Verzenio, the company said Tuesday interim data from a Phase 3 study show proof of a survival benefit among women with metastatic disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,